Skip to main content
. 2019 Feb 21;22:101732. doi: 10.1016/j.nicl.2019.101732

Table 1.

Demographic characteristics of patients with SZ and HCs.

SZ (N = 33) HC (N = 30) p
Age (years) 42.21 ± 10.99 43.33 ± 12.95 0.711
Sex
 Male 16 (48.5) 13 (43.3) 0.682
 Female 17 (51.5) 17 (56.7)
Premorbid IQ 103.03 ± 9.86 107.85 ± 9.34 0.059
Education (years) 13.85 ± 2.06 13.87 ± 3.81 0.982
Number of hospitalization 2.82 ± 3.30
Duration of illness (years) 13.57 ± 8.90
Onset age (years) 27.83 ± 9.83
Dosage of antipsychotics (chlorpromazine equivalent, mg) 495.06 ± 558.53
Positive and negative syndrome scale
 Positive 13.06 ± 6.57
 Negative 16.45 ± 6.19
 General 29.61 ± 8.30
 Total 59.12 ± 18.93
TMT-A (seconds) 31.28 ± 13.35 28.38 ± 10.24 0.351
TMT-B (seconds) 107.47 ± 53.55 84.97 ± 50.40 0.108
Verbal fluency 15.91 ± 4.84 19.00 ± 5.82 0.027
K-AVLT – delayed recall 6.31 ± 3.65 9.89 ± 2.08 < 0.001
SFQ 44.88 ± 11.96 40.14 ± 7.77 0.066
SOFAS 63.73 ± 13.59

HC, healthy control; IQ, intelligence quotient; K-AVLT, Korean Auditory Verbal Learning Test; SFQ, Social Functioning Questionnaire; SOFAS, Social and Occupational Functioning Assessment Scale; SZ, schizophrenia; TMT-A, Trail Making Test-A; TMT-B, Trail Making Test-B.